Laurus Labs bags USFDA zero observations
DSIJ Intelligence / 20 May 2017
The recently listed pharma major Laurus Labs’ API facility of its Vizag unit received the USFDA approval without any Form 483 observations, and its formulation unit received the EIR (establishment inspection report) on May 18, 2017.
The recently listed pharma major Laurus Labs’ API facility of its Vizag unit received the USFDA approval without any Form 483 observations, and its formulation unit received the EIR (establishment inspection report) on May 18, 2017.
The unit, also approved by European regulator, manufactures active pharmaceutical ingredients along with finished dosage formulations and has a manufacturing capacity of 1 billion tablets on an annual basis in APSEZ at Achutapuram, Vizag.
The company, which is soon entering the US generics market, had filed three Abbreviated New Drug Applications (ANDA) and also completed six product validations. Laurus Labs has 20 products in pipeline for its launch in the US markets.
The company is also a major supplier of active pharmaceutical ingredients for anti-retroviral drugs, used for suppressing HIV infection, and hepatitis-C drugs which is used for the treatment of liver infections, for most of the world’s largest generic companies.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.